Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.68 |
| ▸ | POLB | P06746 | 1/20 | 0.68 |
| ▸ | RAB9A | P51151 | 1/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.68 |
| ▸ | BCHE | P06276 | 12/20 | 0.38 |
| ▸ | ACHE | P22303 | 12/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2178816 | 0.98 | NPC1 (0.66) | NPC1POLBRAB9ASMN1; SMN2BCHE | |
| SCHEMBL13334061 | 0.85 | NPC1 (0.67) | NPC1POLBRAB9ASMN1; SMN2BCHE | |
| SCHEMBL13334091 | 0.85 | NPC1 (0.67) | NPC1POLBRAB9ASMN1; SMN2BCHE | |
| Iodide SCHEMBL3312044 | 0.84 | NPC1 (0.65) | NPC1POLBRAB9ASMN1; SMN2BCHE | |
| Bromide SCHEMBL3309394 | 0.84 | NPC1 (0.70) | NPC1POLBRAB9ASMN1; SMN2BCHE | |
| SCHEMBL3603641 | 0.83 | NPC1 (0.96) | NPC1POLBRAB9ASMN1; SMN2BCHE | |
| SCHEMBL3598215 | 0.83 | NPC1 (0.96) | NPC1POLBRAB9ASMN1; SMN2BCHE | |
| SCHEMBL3600997 | 0.83 | NPC1 (0.96) | NPC1POLBRAB9ASMN1; SMN2BCHE | |
| SCHEMBL3606677 | 0.83 | NPC1 (0.96) | NPC1POLBRAB9ASMN1; SMN2BCHE | |
| SCHEMBL3592351 | 0.83 | NPC1 (0.96) | NPC1POLBRAB9ASMN1; SMN2BCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9499518-B2 | Bis-quaternary ammonium salts as pain modulating agents | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2016-11-22 | — | — | US | disclosed |
| US-20160279119-A9 | BIS-QUATERNARY AMMONIUM SALTS AS PAIN MODULATING AGENTS | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2016-09-29 | — | — | US | disclosed |
| US-20160279119-A9 | BIS-QUATERNARY AMMONIUM SALTS AS PAIN MODULATING AGENTS | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2016-09-29 | — | — | US | disclosed |
| US-8178678-B2 | Bis-quaternary ammonium salts and methods for modulating neuronal nicotinic acetylcholine receptors | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2012-05-15 | — | — | US | disclosed |
| US-20110166177-A1 | BIS-QUATERNARY AMMONIUM SALTS AS PAIN MODULATING AGENTS | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2011-07-07 | — | — | US | disclosed |
| US-20100069432-A1 | Bis-Quaternary Ammonium Salts and Methods for Modulating Neuronal Nicotinic Acetylcholine Receptors | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2010-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166177-A1 | BIS-QUATERNARY AMMONIUM SALTS AS PAIN MODULATING AGENTS | RELA, FHIT, OPRL1 | NPC1 3736/4885POLB 2602/4885RAB9A 1249/4885 |
| US-20160279119-A9 | BIS-QUATERNARY AMMONIUM SALTS AS PAIN MODULATING AGENTS | RELA, FHIT, OPRL1 | NPC1 3736/4885POLB 2602/4885RAB9A 1249/4885 |
| US-20100069432-A1 | Bis-Quaternary Ammonium Salts and Methods for Modulating Neuronal Nicotinic Acetylcholine Receptors | CHRNA2, CHRNA5, CHRNA4 | NPC1 1844/4885POLB 3604/4885RAB9A 920/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.